These results confirm tolerability and safety of this novel biological agent in established dSSc and the value of a placebo treated control group in small clinical trials evaluating skin disease in SSc is confirmed. PubMed, Ann Rheum Dis, 2014 Jan 1;73(1):56-61. (Also see: AIMSPRO Clinical Trial, and Diffuse Scleroderma)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.